No disclosed relationships extracted for XBIOyet. The EDGAR pass hasn't reached this filing; the graph grows as filings are read.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Nothing on the wire mentions XBIO yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How XBIO has moved on past release days vs its typical ±3.8% day, and how often it closed up. Computed from daily closes — not a forecast.